Navigation Links
Mesa Labs Reports Higher Quarterly Sales and Earnings
Date:2/11/2008

LAKEWOOD, Colo., Feb. 11 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: MLAB) today reported significantly higher sales and earnings for both its fiscal third quarter and nine months ended December 31, 2007.

Highlights:

-- Third quarter revenue increases 13%

-- Third quarter net income increases 37%

-- Third quarter diluted EPS increases 36%

For the third quarter of fiscal 2008, net sales increased 13 percent to $4,614,000 from $4,095,000 in the same quarter last year. Net income for the quarter increased 37 percent to $1,121,000 or $.34 per diluted share compared to $818,000 or $.25 per diluted share one year ago.

For the first nine months of fiscal 2008, net sales increased 15 percent to $13,768,000 from $11,956,000 in the same period last year. Net income for the first nine months increased 36 percent to $3,415,000 or $1.04 per diluted share compared to $2,520,000 or $.78 per share one year ago.

"The third quarter of fiscal 2008 was another good quarter for Mesa," said John J. Sullivan, President and Chief Operating Officer. "We had good revenue growth and exceptional earnings growth, due largely to our improved gross margins this year. The third quarter is traditionally a weaker quarter for Mesa, but this year we had exceptional growth in the quarter for our DataTrace product line. This was due partially to a very weak Q3 for DataTrace last year and partially to the exceptional performance of our U.S. sales team. DataTrace, has very good momentum going into the last quarter of fiscal 2008. While our other two core product lines, Raven and Medical, experienced relatively little growth in the third quarter, we see these lines recovering in the last quarter of the year to the order rate we saw in the first half," continued John Sullivan. "Looking ahead, we have a number of important initiatives that should foster both short term and long term growth. These include executing a significant new product introduction in DataTrace, increasing our R&D effort in all product lines, and implementing efficiency improvements in all of our operations. As always, we will undertake these initiatives in a cost effective manner to allow for continued earnings growth."

During the third quarter and first nine months of fiscal 2008, sales of the Company's medical products and services were unchanged and increased nine percent, respectively, compared to the prior year periods. For the quarter, small increases of shipments in the meter product line and parts and service were off-set by a decrease in Echo Reprocessors which were discontinued earlier in the fiscal year. The increase for the nine month period was due chiefly to higher sales of the Company's dialysate meters and standard solution products.

During the third quarter and first nine months of fiscal 2008, sales of DataTrace data logger products increased compared to the prior year. For the quarter, DataTrace sales increased 46 percent compared to the same period last year, while sales increased 17 percent for the nine month period compared to the same period last year. The increase in DataTrace sales during the quarter reflects higher shipments of Micropack III temperature and humidity units and an increase in rental revenues. The increase for the nine month period is attributable chiefly to higher Micropack III temperature units and higher service revenues.

Third quarter sales of Raven biological indicator products increased two percent compared to the prior year period. The Raven biological indicator products were acquired on May 4, 2006. For this reason, sales of the company's Raven biological indicator products benefited from an extra five weeks of sales for the current nine month period when compared to the prior year period and were up 27 percent. While order volumes remained strong during the recent quarter, shipments did not keep up with orders due to heavier order volumes late in the quarter and some disruption to manufacturing and shipments due to facility upgrades that were performed the last week of the quarter.

Profitability for the third quarter and nine month periods of fiscal 2008 was up compared to the prior fiscal year due chiefly to the increase in revenues and a gain in our gross margin percentage. For the quarter, net income increased 37 percent and exceeded sales growth which was 13 percent for the quarter. For the first nine month period, net income increased 36 percent and exceeded sales growth which was 15 percent for the period. Net income also benefited from a slightly lower tax rate due to the impact of the Raven acquisition on our overall tax rate.

During the second half of October 2007, we began documentation of our compliance with Section 404 of the Sarbanes-Oxley Act. We are using an outside consulting firm to assist us with this work and expect to incur expenses for this project of at least $100,000 by the end of April 2008. By the end of the third fiscal quarter almost all documentation review was complete and testing is currently scheduled for March and April. Through December 31, 2007, the company had incurred approximately $44,000 of the consulting fees associated with this project.

During the first nine months of fiscal 2008, the Company repurchased 35,848 shares of our common stock under a previously announced buyback plan for approximately $779,000. In addition, the Company has a remaining commitment of approximately $340,000 for automation of certain manufacturing processes for its Raven line of biological indicators.

Mesa Laboratories develops, acquires, manufactures and markets electronic instruments and disposables for industrial, pharmaceutical and medical applications.

This news release contains forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those in any such forward-looking statements. Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company's Annual Report on Form-10KSB for the year ended March 31, 2007 as filed with the Securities and Exchange Commission, and from time to time in the Company's other reports on file with the Commission.

FINANCIAL SUMMARY

STATEMENT OF EARNINGS

(Unaudited)

Quarter Ended Nine Months Ended

December 31 December 31

2007 2006 2007 2006

Net Sales $4,614,000 $4,095,000 $13,768,000 $11,956,000

Cost of Goods 1,527,000 1,633,000 4,494,000 4,427,000

Gross Profit 3,087,000 2,462,000 9,274,000 7,529,000

Operating Expense 1,399,000 1,202,000 4,150,000 3,675,000

Operating Income 1,688,000 1,260,000 5,124,000 3,854,000

Other (Income) &

Expense (54,000) (36,000) (150,000) (104,000)

Earnings Before

Taxes 1,742,000 1,296,000 5,274,000 3,958,000

Income Taxes 621,000 478,000 1,859,000 1,438,000

Net Income $1,121,000 $818,000 $3,415,000 $2,520,000

Earnings Per Share

(Basic) $.35 $.26 $1.08 $.80

Earnings Per Share

(Diluted) $.34 $.25 $1.04 $.78

Average Shares

(Basic) 3,165,000 3,177,000 3,168,000 3,156,000

Average Shares

(Diluted) 3,292,000 3,273,000 3,285,000 3,232,000

BALANCE SHEETS (Unaudited)

Dec. 31 March 31

2007 2007

Cash and Short-

term Investments $5,186,000 $3,346,000

Other Current

Assets 7,654,000 7,496,000

Total Current

Assets 12,840,000 10,842,000

Property and

Equipment 3,621,000 3,521,000

Other Assets 7,614,000 7,991,000

Total Assets $24,075,000 $22,354,000

Liabilities $1,252,000 $1,631,000

Stockholders'

Equity 22,823,000 20,723,000

Total Liabilities

and Equity $24,075,000 $22,354,000


'/>"/>
SOURCE Mesa Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
2. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
3. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
4. Neurobiological Technologies Reports Second Quarter Financial Results
5. Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results
6. Bioniche Reports Fiscal 2008 Second Quarter
7. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
8. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
9. Hot Flashes Not Always to Blame for Sleep Problems in Menopausal Women, Reports the Harvard Womens Health Watch
10. Pathology Reports Good for Breast Cancer Studies
11. American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: